Wound; Hip
Conditions
Keywords
barbed suture, knoteless suture, closure, wound, time, total hip arthroplasty
Brief summary
The STRATAFIX (Ethicon, Johnson and Johnson, Somerville, New Jersey) Knotless Tissue Control suture device is a barbed suture that uses anchor technology to securely engage with the soft tissues while also eliminating the need for knots. The anchors, or barbs, are pressed out of the device core or formed within the core in a geometric pattern and arranged in a tapered manner to allow the device to pass through tissue in the direction toward the needle during closure. These knotless tissue control devices are deployed using a continuous technique, which is anticipated to be faster and more cost-effective than interrupted suturing.
Detailed description
Preclinical and biomechanical studies have demonstrated efficacy in cosmetic skin and deep tissue closures.\[1\], \[2\] In addition, barbed sutures have been shown to provide water-tight closure and wound strength comparable to or superior to closure with conventional sutures. Many comparative studies have been published contrasting barbed sutures to conventional closure techniques in multiple surgical fields. \[3\], \[4\] Various studies have evaluated the outcomes of different barbed suture devices, however there are no reports assessing the length of closure times using STRATAFIX (Ethicon, Johnson and Johnson, Somerville, New Jersey) Knotless Tissue Control Devices during deep closure in total hip arthroplasty. Stephens et al. \[5\] performed a prospective randomized study of 500 total knee arthroplasty patients who received either barbed suture (250) or conventional sutures (250) for deep closure of the surgical wound. The mean operating time was significantly shorter in the barbed group as compared to conventional group (64.3 vs 68.1 minutes, p=\<0.001). In a study of 80 TKA (61 barbed, 19 conventional deep sutures) and 54 THA patients (37 barbed, 17 conventional deep sutures), Smith et al. \[6\] found significantly shorter closure time in the barbed suture group (16.78 vs. 26.5 minutes, p\<0.001). One study reports one the use of Stratfix suture for intracorporeal suturing in myomectomy. Giampaolino et al. \[7\] performed a prospective randomized study on 47 patients and evaluated the mean operative time for laparoscopic posterior myomectomy using Stratafix or conventional suture for intracorporeal suturing. There was a significant decrease in mean operative time associated with use of Stratafix suture as compared to conventional suture (66.3 vs 73 minutes, p=0.005). This prospective randomized single-center study will examine the outcomes, mainly closure time, of deep closure during total hip arthroplasty using the STRATAFIX Symmetric PDS Plus (Ethicon, Johnson and Johnson, Somerville, New Jersey) barbed suture compared to interrupted VICRYL suture (Ethicon, Johnson and Johnson, Somerville, New Jersey).
Interventions
Sponsors
The Cleveland Clinic
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Males and females, between the ages of 18 to 80 years at the time of signing the informed consent document. 2. Understand and voluntarily sign an informed consent document prior to any study-related assessments/procedures are conducted. 3. Able to adhere to the study visit schedule and other protocol requirements. 4. Able to fluently speak and understand the local language 5. If female, is non-pregnant (negative pregnancy test results at the baseline/randomization visit) and non-lactating. 6. End-stage osteoarthritis patients planning to undergo primary total hip arthroplasty 7. BMI less than 40 kg/m2
Exclusion criteria
1. BMI greater than or equal to 40 kg/m2. 2. History of known bleeding disorder. 3. History of medical co-morbidity that may result in poor wound healing (i.e. diabetes mellitus, peripheral vascular disease). 4. Patients \<18 or \>80 years of age. 5. Patients who are prisoners. 6. Mentally unable to sign informed consent. 7. Has an uncontrolled illness that, in the opinion of the investigator, is likely to cause the patient to be withdrawn from the trial or would otherwise interfere with interpreting the results of the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Time to Close, Minutes | Day of surgery | Time from first needle insertion to complete skin closure per protocol |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Wound Complications | 90 days postoperative | Superficial wound infection, deep wound infection, periprosthetic joint infection, wound hematoma, and wound dehiscence. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| STRATAFIX GROUP For the active arm of the study, wound closure will be performed similarly in 3 layers with the use of barbed equivalents at every layer: STRATIFIX symmetric PDS Plus #1 will be used to close the deep fascia and muscles . The subcutaneous fat layer will be then closed with simple interrupted knots using number 2-0 braided absorbable sutures (Vicryl), followed by closure of the subcutaneous layer using a number 2-0 monofilament absorbable suture with inverted interrupted knots (Monocryl, Ethicon; Johnson & Johnson) followed by the use of steri-strips and glue
STRATIFIX: STRATIFIX symmetric PDS Plus; Stratifix knotless suture | 30 |
| CONTROL GROUP For the control arm of the study, wound closure will be performed similarly in 3 layers with the use of vicryl to closure the deep fascia and muscles. The subcutaneous fat layer will be then closed with simple interrupted knots using number 2-0 braided absorbable sutures (Vicryl), followed by closure of the subcutaneous layer using a number 2-0 monofilament absorbable suture with inverted interrupted knots (Monocryl, Ethicon; Johnson & Johnson) followed by the use of steri-strips and glue
VICRYL: Vicryl #1 | 30 |
| Total | 60 |
Baseline characteristics
| Characteristic | Total | STRATAFIX GROUP | CONTROL GROUP |
|---|---|---|---|
| Age, Continuous | 63 years STANDARD_DEVIATION 12 | 61 years STANDARD_DEVIATION 13 | 66 years STANDARD_DEVIATION 10 |
| Race and Ethnicity Not Collected | 0 Participants | — | — |
| Sex: Female, Male Female | 32 Participants | 13 Participants | 19 Participants |
| Sex: Female, Male Male | 28 Participants | 17 Participants | 11 Participants |
| Wound length, cm | 12 centimeters STANDARD_DEVIATION 1.6 | 12 centimeters STANDARD_DEVIATION 1.8 | 13 centimeters STANDARD_DEVIATION 1.4 |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 30 | 0 / 30 |
| other Total, other adverse events | 1 / 30 | 1 / 30 |
| serious Total, serious adverse events | 0 / 30 | 0 / 30 |
Outcome results
Primary
Time to Close, Minutes
Time from first needle insertion to complete skin closure per protocol
Time frame: Day of surgery
Population: total hip arthroplasty patients
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| STRATAFIX GROUP | Time to Close, Minutes | 18.0 minutes | Standard Deviation 0.35 |
| CONTROL GROUP | Time to Close, Minutes | 21.0 minutes | Standard Deviation 0.43 |
Secondary
Number of Participants With Wound Complications
Superficial wound infection, deep wound infection, periprosthetic joint infection, wound hematoma, and wound dehiscence.
Time frame: 90 days postoperative
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| STRATAFIX GROUP | Number of Participants With Wound Complications | 1 Participants |
| CONTROL GROUP | Number of Participants With Wound Complications | 1 Participants |